Amyn A Habib

List of Publications by Year
in descending order

35 papers	2,103 citations	279798 23 h-index	414414 32 g-index
35 all docs	35 docs citations	35 times ranked	3970 citing authors

#	Article	IF	Citations
1	Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nature Nanotechnology, 2022, 17, 206-216.	31.5	46
2	Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment. Neoplasia, 2021, 23, 189-196.	5.3	38
3	Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway. Molecular Cancer Therapeutics, 2021, 20, 1904-1915.	4.1	15
4	Elimination of Radiation-Induced Senescence in the Brain Tumor Microenvironment Attenuates Glioblastoma Recurrence. Cancer Research, 2021, 81, 5935-5947.	0.9	62
5	Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. Nature Communications, 2021, 12, 7014.	12.8	6
6	EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nature Cancer, 2020, 1, 394-409.	13.2	51
7	Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. Neuro-Oncology, 2019, 21, 1529-1539.	1.2	21
8	An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases. Nature Communications, 2019, 10, 5108.	12.8	148
9	Radiation-Induced DNA Damage Cooperates with Heterozygosity of TP53 and PTEN to Generate High-Grade Gliomas. Cancer Research, 2019, 79, 3749-3761.	0.9	23
10	DRES-17. ACTIVATION OF FGF SIGNALING PATHWAY CONFERS RESISTANCE TO EGFR INHIBITION IN GBM. Neuro-Oncology, 2018, 20, vi79-vi79.	1.2	0
11	Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2018, 77, 542-548.	1.7	34
12	TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. Journal of Clinical Investigation, 2018, 128, 2500-2518.	8.2	73
13	Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis. Journal of Neuro-Oncology, 2017, 133, 183-192.	2.9	30
14	Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential. Molecular Imaging, 2017, 16, 153601211770872.	1.4	15
15	A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nature Neuroscience, 2017, 20, 1074-1084.	14.8	82
16	Analysis of Constitutive EGFR Signaling Regulating IRF3 Transcriptional Activity in Cancer Cells. Methods in Molecular Biology, 2017, 1652, 183-189.	0.9	0
17	DRES-06. PRIMARY RESISTANCE TO EGFR INHIBITION IN GLIOBLASTOMA IS MEDIATED BY AÂTNF-JNK-Axl-ERK SIGNALING AXIS. Neuro-Oncology, 2017, 19, vi65-vi65.	1.2	0
18	Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. Nature Communications, 2017, 8, 1913.	12.8	62

#	ARTICLE	IF	CITATIONS
19	Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma. Molecular Cancer Research, 2016, 14, 928-940.	3.4	53
20	Ligand-Independent EGFR Signaling. Cancer Research, 2015, 75, 3436-3441.	0.9	166
21	The role of NF-ÎºB in the pathogenesis of glioma. Molecular and Cellular Oncology, 2014, 1, e963478.	0.7	71
22	Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. Nature Communications, 2014, 5, 5811.	12.8	72
23	High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade IIâ€"III astrocytomas and oligoastrocytomas. Journal of Neuro-Oncology, 2014, 117, 183-189.	2.9	34
24	Hippocampal Sclerosis in Dementia, Epilepsy, and Ischemic Injury: Differential Vulnerability of Hippocampal Subfields. Journal of Neuropathology and Experimental Neurology, 2014, 73, 136-142.	1.7	57
25	Opposing Effect of EGFRWT on EGFRvIII-Mediated NF-ÎºB Activation with RIP1 as a Cell Death Switch. Cell Reports, 2013, 4, 764-775.	6.4	38
26	Cytoplasmic TRADD Confers a Worse Prognosis in Glioblastoma. Neoplasia, 2013, 15, 888-897.	5.3	16
27	Improved protein arrays for quantitative systems analysis of the dynamics of signaling pathway interactions. Proteome Science, 2011, 9, 53.	1.7	8
28	Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance. Neoplasia, 2010, 12, 675-684.	5.3	381
29	The receptor interacting protein 1 mediates a link between NFÎºB and PI3-kinase signaling. Cell Cycle, 2009, 8, 2671-2672.	2.6	3
30	RIP1 Activates PI3K-Akt via a Dual Mechanism Involving NF-ÎºBâ€"Mediated Inhibition of the mTOR-S6K-IRS1 Negative Feedback Loop and Down-regulation of PTEN. Cancer Research, 2009, 69, 4107-4111.	0.9	53
31	The Receptor Interacting Protein 1 Inhibits p53 Induction through NF-ÎºB Activation and Confers a Worse Prognosis in Glioblastoma. Cancer Research, 2009, 69, 2809-2816.	0.9	134
32	The death domainâ€"containing kinase RIP1 regulates p27 Kip1 levels through the PI3Kâ€"Aktâ€"forkhead pathway. EMBO Reports, 2008, 9, 766-773.	4.5	13
33	Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells. Cancer Research, 2006, 66, 867-874.	0.9	149
34	Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways. Molecular Cancer Research, 2003, 1, 219-33.	3.4	33
35	The Epidermal Growth Factor Receptor Engages Receptor Interacting Protein and Nuclear Factor-ÎºB (NF-ÎºB)-inducing Kinase to Activate NF-ÎºB. Journal of Biological Chemistry, 2001, 276, 8865-8874.	3.4	116